menu search

EMMLF / Okyo Pharma successfully closes US$2.5mln US fundraise

Okyo Pharma successfully closes US$2.5mln US fundraise
Okyo Pharma Ltd (LSE:OKYO, OTCQB:EMMLF) has confirmed it has successfully closed a US$2.5mln US fundraiser. The group, which is developing a treatment for dry eye disease (DED), issued American depositary shares priced at US$4 each. Read More
Posted: May 20 2022, 02:25
Author Name: Proactive Investors
Views: 112585

EMMLF News  

Why Is OKYO Pharma (OKYO) Stock Down 19% Today?

By InvestorPlace
August 1, 2023

Why Is OKYO Pharma (OKYO) Stock Down 19% Today?

OKYO Pharma (NASDAQ: OKYO ) stock is falling on Tuesday even after the biopharmaceutical company withdrew a public offering. According to a press rel more_horizontal

OKYO Pharma inks collaboration with Tufts Medical Center

By Proactive Investors
July 28, 2023

OKYO Pharma inks collaboration with Tufts Medical Center

OKYO Pharma Ltd (NASDAQ:OKYO) has revealed a new partnership with Tufts Medical Center to conduct an open-label clinical trial to assess the efficacy more_horizontal

OKYO Pharma begins OK-101 phase 2 dosing

By Proactive Investors
June 6, 2023

OKYO Pharma begins OK-101 phase 2 dosing

OKYO Pharma said patients are being dosed in a randomise portion of a phase 2 trial for its OK-101 drug to treat dry eye disease (DED). The ophthalmo more_horizontal

OKYO Pharma receives US FDA license to start Phase 2 study

By Proactive Investors
December 22, 2022

OKYO Pharma receives US FDA license to start Phase 2 study

OKYO Pharma Ltd (LSE:OKYO, NASDAQ:OKYO) said its dry eye disease treatment has received its investigational new drug (IND) application from the US Fo more_horizontal

Okyo Pharma successfully closes US$2.5mln US fundraise

By Proactive Investors
May 20, 2022

Okyo Pharma successfully closes US$2.5mln US fundraise

Okyo Pharma Ltd (LSE:OKYO, OTCQB:EMMLF) has confirmed it has successfully closed a US$2.5mln US fundraiser. The group, which is developing a treatment more_horizontal

OKYO Pharma to raise US$2.5mln in the US

By Proactive Investors
May 17, 2022

OKYO Pharma to raise US$2.5mln in the US

OKYO Pharma Ltd, the specialist in inflammatory dry eye disease, said it is raising a gross US$2.5mln by issuing American depositary shares priced at more_horizontal

OKYO Pharma: Developer Of Next Generation Ocular Therapeutics

By Seeking Alpha
March 24, 2022

OKYO Pharma: Developer Of Next Generation Ocular Therapeutics

OKYO Pharma: Developer Of Next Generation Ocular Therapeutics more_horizontal

OKYO Pharma receives US patent for dry eye disease drug covering neuropathic pain

By Proactive Investors
February 23, 2022

OKYO Pharma receives US patent for dry eye disease drug covering neuropathic pain

OKYO Pharma Ltd said it has been issued a US patent for its dry eye disease candidate (DED) OK-101. The key claim in the application covered the drug more_horizontal


Search within

Pages Search Results: